ANIX.US Anixa Biosciences Inc

Healthcare Biotechnology USA Stocks
2.62 USD
Close of Nov 13, 2026
2.32 5.46
Market cap
USD 91.1M
P/E
-
P/B
6.44x
ROE
-71.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jul 2026.

Is ANIX.US undervalued?

Graham number

The Graham number of Anixa Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Anixa Biosciences Inc fundamental analysis

No fundamental analysis for Anixa Biosciences Inc yet.

Anixa Biosciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Anixa Biosciences Inc

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a …

Full company profile